Table 2.
IPT and ART initiation, and patient outcomes
| CD4≤350 | CD4>350 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total (n=2,138) | TST-negative (n=1,202) | TST-positive* (n=278) | TST-unknown (n=658) | p-value | Total (n=1,976) | TST-negative (n=1,063) | TST-positive* (n=379) | TST-unknown (n=534) | p-value | |
| IPT and ART | ||||||||||
| IPT | 260 (12%) | 33 (3%) | 219 (79%) | 8 (1%) | <0.001 | 359 (18%) | 32 (3%) | 319 (84%) | 8 (2%) | <0.001 |
| ART** | 1,993 (93%) | 1,152 (96%) | 263 (95%) | 578 (88%) | <0.001 | 813 (41%) | 473 (45%) | 142 (37%) | 198 (37%) | 0.01 |
| IPT and ART | 251 (12%) | 15 (1%) | 212 (76%) | 8 (1%) | <0.001 | 136 (7%) | 15 (1%) | 118 (31%) | 3 (1%) | <0.001 |
| Outcomes | ||||||||||
| TB | 170 (8%) | 63 (5%) | 34 (12%) | 73 (11%) | <0.001 | 92 (5%) | 28 (3%) | 32 (8%) | 32 (6%) | <0.001 |
| Died*** | 254 (12%) | 122 (10%) | 24 (9%) | 108 (16%) | <0.001 | 115 (6%) | 56 (5%) | 20 (5%) | 39 (7%) | 0.23 |
Abbreviations: TST, tuberculin skin test; IPT, isoniazid preventive therapy; ART, antiretroviral therapy; TB, tuberculosis
*
155 patients converted from TST-negative to -positive over follow-up
**
382 (9%) patients were on ART at baseline (180 [8%] CD4≤350, 202 [10%] CD4>350) and 37 (1%) initiated ART after a TB diagnosis (22 [1%] CD4≤350, 15 [1%] CD4>350)
***
73 (2%) died after a TB diagnosis (53 [2%] CD4≤350 vs. 20 [1%] CD4>350, p<0.001)